Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-
ABL1-negative myeloproliferative neoplasms and are characterized by relatively long …

Major progress has been recently made in understanding the molecular pathogenesis of
myeloproliferative neoplasms (MPN). Mutations in one of four genes—JAK2, MPL, CALR …

Although clinically tested JAK inhibitors reduce splenomegaly and systemic symptoms,
molecular responses are not observed in most myeloproliferative neoplasm (MPN) patients …

Since the discovery of the JAK 2 V617F mutation in the majority of the myeloproliferative
neoplasms (MPN) of polycythemia vera, essential thrombocythemia and primary …

Megakaryocytes are rare cells found in the bone marrow, responsible for the everyday
production and release of millions of platelets into the bloodstream. Since the discovery and …

Recurrent somatic mutations in the JAK2, MPL, and CALR genes have been described in
patients diagnosed with Philadelphia-negative myeloproliferative neoplasms (MPN) …

Constitutive JAK-STAT pathway activation occurs in most myeloproliferative neoplasms as
well as in a significant proportion of other hematologic malignancies, and is frequently a …

Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm where severity as well
as treatment complexity is mainly attributed to a long lasting disease and presence of bone …

Recent discoveries have significantly expanded our previous knowledge about the role of
bone marrow mesenchymal stem cells (BMSCs) in hematopoiesis. BMSCs and their …

Objectives: To evaluate the mutation frequency of JAK2 V617F, JAK2 exon 12, MPL exon
10, and CALR exon 9 and the value of the combined tests in the diagnosis of BCR-ABL1 …